secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2026-07-15T20:18:23+00:00
Accession:  0001493152-26-033364
Event type: litigation
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma settles $398,740 claims via share issuance; creates Series N preferred with 75M votes per share
--------------------------------------------------------------------------------

- Court approved settlement with Trillium Partners: Regen will issue shares (common or Series A preferred) to satisfy $398,740 in claims; shares sold by plaintiff, 65% of net proceeds to plaintiff.
- Potential dilution: number of shares indeterminable; as of April 17, 2026, common shares outstanding ~402.9M; CEO David Koos is a creditor and will be paid after one year.
- Created Series N Preferred Stock: 1,000 shares authorized, each with 75 million votes, enabling concentrated voting control.
- Changed auditor: BCRG replaced by Simon & Edward LLP after acquisition; no disagreements, but prior reports had going concern qualification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000149315226033364/0001493152-26-033364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000149315226033364/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-033364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer